Edition:
United States

Eisai Co Ltd (ESALY.PK)

ESALY.PK on OTC Markets Group

62.78USD
29 Apr 2016
Change (% chg)

$-0.22 (-0.36%)
Prev Close
$63.00
Open
$63.00
Day's High
$63.01
Day's Low
$62.78
Volume
849
Avg. Vol
4,291
52-wk High
$71.86
52-wk Low
$55.81

ESALY.PK

Chart for ESALY.PK

About

Eisai Co., Ltd. is mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of drugs for pharmaceutical, over-the-counter and diagnostic uses. The Others segment manufactures and... (more)

Overall

Beta: -0.08
Market Cap(Mil.): $18,187.84
Shares Outstanding(Mil.): 296.57
Dividend: 0.57
Yield (%): 1.94

Financials

  ESALY.PK Industry Sector
P/E (TTM): 58.98 34.29 45.26
EPS (TTM): 1.07 -- --
ROI: 4.37 13.02 12.52
ROE: 6.74 13.71 13.41
Search Stocks

BRIEF-Eisai signed cooperation agreements with Pharmstandard

* Co, Pharmstandard signed cooperation agreements relating to localised production of Eisai products in Russia Source text for Eikon: Further company coverage: (Reporting by Vishal Sridhar)

Apr 05 2016

FDA approves Eisai's drug Halaven for type of soft tissue cancer

The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer.

Jan 29 2016

CORRECTED-FDA approves Eisai's drug Halaven for type of soft tissue cancer (Jan. 28)

Jan 28 The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer.

Jan 29 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $111.66 -0.82
GlaxoSmithKline plc (GSK.L) 1,459.00p -30.00
Novartis AG (NOVN.S) CHF73.20 -1.60
Merck & Co., Inc. (MRK.N) $54.76 -0.98
AstraZeneca plc (AZN.L) 3,928.00p -31.50
Pfizer Inc. (PFE.N) $32.67 -0.24
Bristol-Myers Squibb Co (BMY.N) $71.80 -0.46
Bristol-Myers Squibb Co (BMYMP.PK) $1,079.03 --
Sanofi SA (SASY.PA) €72.11 -4.08
Roche Holding Ltd. (ROG.S) CHF242.50 -4.80

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MarketLine
$50.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks